Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Conexeu Sciences Inc.
Market Cap
$89.11M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$89.36M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$88.52M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$88.17M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$89.15M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$87.74M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$91.51M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$92.54M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$84.61M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $89.11M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $89.36M | -150.95% | -77.89% | -62.90% | -47.80% |
| ImmuCell Corporation (ICCC)vs › | $88.52M | 2.51% | -5.84% | -10.75% | -7.81% |
| CareCloud, Inc. (CCLD)vs › | $88.17M | 45.93% | 16.96% | -19.36% | -13.87% |
| Equillium, Inc. (EQ)vs › | $89.15M | -32.15% | -60.32% | -93.79% | -79.41% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $87.74M | -85.65% | -57.41% | -45.73% | -8.61% |
| electroCore, Inc. (ECOR)vs › | $91.51M | N/A | 329.82% | 69.21% | 21.28% |
| Biomea Fusion, Inc. (BMEA)vs › | $92.54M | -268.09% | -238.76% | -155.55% | -124.74% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.61M | N/A | 1.45% | 25.22% | -14.52% |
| Humacyte, Inc. (HUMA)vs › | $84.55M | -309.44% | -515.53% | -464.77% | -329.14% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
